The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
== Further reading == Nature Bone Marrow Transplantation (Nature Publishing Group) – specialist scientific journal with articles on bone marrow biology and clinical uses. Cooper, B (2011). "The origins of bone marrow as the seedbed of our blood: from antiquity to the time of Osler". Baylor University Medical Center Proceedings. 24 (2): 115–8. doi:10.1080/08998280.2011.11928697. PMC 3069519. PMID 21566758. Wang J, Liu X, Lu H, Jiang C, Cui X, Yu L, Fu X, Li Q, Wang J (2015). "CXCR4(+)CD45(-) BMMNC subpopulation is superior to unfractionated BMMNCs for protection after ischemic stroke in mice". Brain Behav. Immun. 45: 98–108. doi:10.1016/j.bbi.2014.12.015. PMC 4342301. PMID 25526817.
The black-necked spitting cobra (Naja nigricollis) is a species of spitting cobra found mostly in Sub-Saharan Africa. They possess medically significant venom, although the mortality rate for untreated bites on humans is relatively low (~5–10%). Like other spitting cobras, this species is known for its ability to project venom at a potential threat. The venom is an irritant to the skin and eyes. If it enters the eyes, symptoms include extreme burning pain, loss of coordination, partial loss of vision and permanent blindness. N. nigricollis is known for its tendency to liberally spit venom with only the slightest provocation. However, this aggressiveness is counterbalanced by it being less prone to bite than other related species. The venom of the black-necked spitting cobra is somewhat unique among elapids in that it consists primarily of cytotoxins, but with other components also. It retains the typical elapid neurotoxic properties while combining these with highly potent cytotoxins (necrotic agents) and cardiotoxins. Bite symptoms include severe external hemorrhaging and tissue necrosis around the bite area and difficulty breathing. Although mortality rate in untreated cases is low (~5–10%), when death occurs it is usually due to asphyxiation by paralysis of the diaphragm. The LD50 of this species is 2 mg/kg SC and 1.15 mg/kg IV. The average venom yield per bite of this species is 200 to 350 mg (dry weight) according to Minton (1974).
Major Force reappears in Battle for Blüdhaven, a series set a year after the events of Infinite Crisis, as the leader of project S.H.A.D.E. In issue #5, Major Force brutally beats Outsiders member Major Victory and rips off his right arm. He also picks a fight with Hal Jordan, having vowed to kill Green Lanterns on sight after his last encounter with Kyle Rayner. Captain Atom drains Major Force of his energy, leaving him a deflated husk. Major Force is later seen reconstituted and a part of a new regiment of S.H.A.D.E. soldiers. A battle ensues with Uncle Sam and the Freedom Fighters for the soul of America, wherein Major Force is quickly dispatched by Miss America. Major Force later appears as a member of the Secret Society during the wedding of Green Arrow and Black Canary.
Sources: en.wikipedia.org
=== Catalysts and reagents === Because Fe is inexpensive and nontoxic, much effort has been devoted to the development of Fe-based catalysts and reagents. Iron is however less common as a catalyst in commercial processes than more expensive metals. In biology, Fe-containing enzymes are pervasive. Iron catalysts are traditionally used in the Haber–Bosch process for the production of ammonia and the Fischer–Tropsch process for conversion of carbon monoxide to hydrocarbons for fuels and lubricants. Powdered iron in an acidic medium is used in the Bechamp reduction, the conversion of nitrobenzene to aniline.
Death Life-threatening adverse drug experience Inpatient hospitalization or prolongation of existing hospitalization Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions Congenital anomaly/birth defect Important medical events (IME) that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition."
1994 Malaysian football scandal 1999 Chinese football match-fixing scandal 2001 Chinese football match-fixing scandal 2003–2009 Chinese football match-fixing scandals Apito Dourado (2004) – a match fixing scandal in Portuguese football involving FC Porto, Boavista, and União de Leiria. Bundesliga scandal (2005) – a match fixing scandal in German football centering on disgraced referee Robert Hoyzer. Caso Genoa (2005) Brazilian football match-fixing scandal (2005) – a match fixing scandal involving referees in Brazil. 2006 Calciopoli scandal – a match fixing scandal in Italian football involving several major teams, including three of the country's four qualifiers to the 2006–07 UEFA Champions League. In the Commonwealth of Independent States Cup 2006, the Armenian champion Pyunik refused to play with an Azerbaijani team, PFC Neftchi. The team Pyunik defeated the Ukrainian team Shakhtar Donetsk 3–1 in the quarter-final, when it already knew that in case of victory they would have to play against Neftchi. After the match, they told the referee they would not play against an Azerbaijani team and later that evening left Moscow on an airplane. The Russian Football Union gave Shakhtar Donetsk a technical victory 3–0 so they could play in the half-final instead of Pyunik, but Shakhtar Donetsk declined the offer stating that "[W]e would really want to play in the half-final, but we don't want to get there by any other way then sport".
Sources: en.wikipedia.org
== External links == Waite, Mike. "Democratic Left day conference: Radical Roots, London, 14 December 1996". Communist History Network Newsletter. Politics Section of the School of Social Sciences at the University of Manchester. Archived from the original on 17 July 2011. Retrieved 9 February 2010. Democratic Left on the Internet Archive
Murex purple was a very important industry in many Phoenician territories and Carthage was no exception. Traces of this once very lucrative industry are still visible in many Punic sites such as Kerkouane, Zouchis, Djerba and even in Carthage itself. According to Pliny, Meninx (today's Djerba) produced the best purple in Africa which was also ranked second only after Tyre's. It was found also at Essaouira (Morocco). The Royal purple or Imperial purple was probably used until the time of Augustine of Hippo (354–430) and before the demise of the Roman Empire.
== History == Pantoprazole was discovered by scientists at Byk Gulden, a subsidiary of Altana; the drug discovery program started in 1980, producing pantoprazole in 1985. The compound was actually created by chemists working to scale up a different chemical that had been chosen as a development candidate. Byk Gulden partnered with Smith Kline & French in 1984. The compound's development names were BY1029 and SK&F96022. By 1986 the companies had created the sodium salt, pantoprazole sodium sesquihydrate, and decided to develop it as it was more soluble and stable, and was more compatible with other ingredients used in the formulation. It was first marketed in Germany in 1994. Wyeth licensed the US patent from Altana, and obtained marketing approval from the US FDA in 2000 under the trade name Protonix. In 2004, worldwide sales of the drug were $3.65 billion, about half of which were in the US. In 2007, Altana's drug business was acquired by Nycomed. Nycomed was in turn acquired by Takeda in 2011 and Wyeth was acquired by Pfizer in 2009. The patent protecting the drug was set to expire in 2010, but Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) in 2007, and Wyeth and Nycomed sued Teva for patent infringement, but Teva decided to launch its generic drug "at risk" that year, before the patent had been invalidated. Wyeth launched an authorized generic in 2008. Pfizer and Takeda's patent exclusivity expired in 2010, and an administrative exclusivity they had for pediatric use expired in January 2011, and full generic competition began.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.